Galectin Therapeutics Inc.
GALT
$1.38
$0.010.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -14.56% | -8.09% | -11.07% | -1.63% | -5.91% |
| Total Depreciation and Amortization | 12.12% | 12.50% | 12.90% | -81.48% | 3.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.71% | 25.03% | 25.46% | -2.54% | 24.63% |
| Change in Net Operating Assets | -51.18% | 165.79% | 2,347.65% | 11.01% | -5.84% |
| Cash from Operations | -26.70% | 5.14% | 9.49% | -1.39% | -6.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00% | 33.33% | 0.00% | 50.00% | 200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.77% | -96.25% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22.00% | 0.86% | 34.70% | 100.17% | 300.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -249.12% | 47.83% | 222.86% | 141.69% | 133.57% |